Fox Chase, Sylvester collaborate with Pfizer to identify genetic drivers of cancer disparities

Weiran Feng, Hanzhi Luo, Qing Chen join Fox Chase Cancer Center as assistant professors

Weiran FengHanzhi LuoQing ChenWeiran Feng, Hanzhi Luo and Qing Chen will join Fox Chase Cancer Center as assistant professors.

January 31, 2025

Vol.51 No.04

In Brief

Roland Dunbrack appointed co-leader of Cancer Signaling and Microenvironment Research Program at Fox Chase

Roland Dunbrack was named co-leader of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center alongside the program’s current leader, Edna Cukierman.

January 17, 2025

Vol.51 No.02

In Brief

UH Cancer Center and John A. Burns School of Medicine form initiative focused on health outcome disparities in Hawai‘i and the Pacific

The University of Hawai‘i Cancer Center and the John A. Burns School of Medicine are forming Ka ʻUmeke Lama, an initiative to transform cancer care in Hawaiʻi and the Pacific.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.

January 10, 2025

Vol.51 No.01

Drugs & Targets

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

FDA granted accelerated approval to encorafenib (Braftovi) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.

January 10, 2025

Vol.51 No.01

Art exhibit at University of Miami Sylvester bridges North and South America

“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.

December 13, 2024

Vol.50 No.46

By Claire Marie Porter

Fox Chase, Sylvester collaborate with Pfizer to identify genetic drivers of cancer disparities

YOU MAY BE INTERESTED IN

Weiran Feng, Hanzhi Luo, Qing Chen join Fox Chase Cancer Center as assistant professors

Roland Dunbrack appointed co-leader of Cancer Signaling and Microenvironment Research Program at Fox Chase

UH Cancer Center and John A. Burns School of Medicine form initiative focused on health outcome disparities in Hawai‘i and the Pacific

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

Art exhibit at University of Miami Sylvester bridges North and South America

Renew today!

Subscriber content

Never miss an issue!

Login